Alpha 2 ‐adrenergic agents in anaesthesia
1993; Wiley; Volume: 37; Issue: 5 Linguagem: Inglês
10.1111/j.1399-6576.1993.tb03743.x
ISSN1399-6576
Autores Tópico(s)Veterinary Pharmacology and Anesthesia
ResumoActa Anaesthesiologica ScandinavicaVolume 37, Issue 5 p. 433-448 Alpha2-adrenergic agents in anaesthesia R. AANTAA, Corresponding Author R. AANTAA Department Anaesthesiology of, Turku University HospitalOrion-Farmos Pharmaceuticals Farmos Research P.O. Box 425 SF-20101 Turku FinlandSearch for more papers by this authorM. SCHEININ, M. SCHEININ Department of Pharmacology, University of Turku, Turku, FinlandSearch for more papers by this author R. AANTAA, Corresponding Author R. AANTAA Department Anaesthesiology of, Turku University HospitalOrion-Farmos Pharmaceuticals Farmos Research P.O. Box 425 SF-20101 Turku FinlandSearch for more papers by this authorM. SCHEININ, M. SCHEININ Department of Pharmacology, University of Turku, Turku, FinlandSearch for more papers by this author First published: July 1993 https://doi.org/10.1111/j.1399-6576.1993.tb03743.xCitations: 98AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Longnecker D E. Alpine anesthesia: can pretreatment with clonidine decrease the peaks and valleys? (editorial) Anesthesiology 1987: 67: 1– 2. 2 Bloor B C. Clonidine and other alpha2adrenergic agonists: an important new drug class for the perioperative period. Semin Anesth 1988; 7: 170– 177. 3 Maze M, Tranquilli W. Alpha–2 adrenoceptor agonists: defining the role in clinical anesthesia. Anesthesiology 1991; 74: 581– 605. 4 Vickery R G, Sheridan B C, Segal I S, Maze M. Anesthetic and hemodynamic effects of the stereoisomers of medetomidine, an α2–adrenergic agonist, in halothane–anesthetized dogs. Anesth Analg 1988; 67: 611– 615. 5 Tranquilli W J, Thurmon J C, Corbin J E, Benson G J, Davis L E. Halothane–sparing effect of xylazine in dogs and subsequent reversal with tolazoline. J Vet Pharmacol Ther 1984; 7: 23– 28. 6 Clarke K W, England G C W. Medetomidine, a new sedative–analgesic for use in the dog and its reversal with antipamezole. J Small Anim Pract 1989; 30: 343– 348. 7 Eisenach J C, Lysak S Z, Viscomin C M. Epidural clonidine analgesia following surgery; phase I. Anesthesiology 1989; 71: 640– 646. 8 Kalso E A, Pöyhiä R, Rosenberg P H. Spinal antinociception by dexmedetomidine, a highly selective α2–adrenergic agonist. Pharmacol Toxicol 1991; 68: 140– 143. 9 Langer S Z. Presynaptic regulation of catecholamine release. Biochem Pharmacol 1974; 23: 1793– 1800. 10 Langer S Z. Presynaptic regulation of the release of catecholamines. Pharmacol Rev 1981; 32: 337– 362. 11 Starke K. Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol Biochem Pharmacol 1977; 77: 1– 124. 12 Cheung Y–D, Barnett D B, Nahorski S R. [3H]rauwolscine and [3H] yohimbine binding to rat cerebral and human platelet membranes: possible heterogeneity of α2–adrenoceptors. Eur J Pharmacol 1982; 84: 79– 85. 13 Bylund D B. Heterogeneity of alpha–2 adrenergic receptors. Pharmacol Biochem Behav 1985; 22: 835– 843. 14 Starke K. α–Adrenoceptor subclassification. Rev Physiol Biochem Pharmacol 1981; 88: 199– 236. 15 Ernsberger P, Meeley M P, Mann J J, Reis D J. Clonidine binds to imidazoline binding sites as well as α–adrenoceptors in the ventrolateral medulla. Eur J Pharmacol 1987; 134: 1– 13. 16 Kamisaki Y, Ishikawa T, Takao Y, Omodani H, Kuno N, Itoh T. Binding of [3H]p–aminoclonidine to two sites, α2–adrenocep–tors and imidazoline binding sites: distribution of imidazoline binding sites in rat brain. Brain Res 1990; 514: 15– 21. 17 Bylund D B. Subtypes of α–adrenoceptors: pharmacological and molecular biological evidence converge. Trends Pharmacol Sci 1988; 9: 356– 361. 18 Harrison J K, Pearson W R, Lynch K. Molecular characterization of al– and α2–adrenoceptors. Trends Pharmacol Sci 1991; 12: 62– 67. 19 Lomasney J W, Cotecchia S, Lefkowitz R J, Caron M G. Molecular biology of α–adrenergic receptors: implications for receptor classification and for structure–function relationships. Biochim Biophys Acta 1991; 1095: 127– 139. 20 Kobilka B K, Matsui H, Kobilka T S et al. Cloning, sequencing, and expression of the gene coding for the human platelet, α2–adrenergic receptor. Science 1987; 238: 650– 656. 21 Regan J W, Kobilka T S, Yang–Feng T L, Caron M G, Lefkowitz R J, Kobilka B K. Cloning and expression of a human kidney cDNA for an α2–adrenergic receptor subtype. Proc Natl Acad Sci USA 1988; 85: 6301– 6305. 22 Lomasney J W, Lorenz W, Allen L F et al. Expansion of the α2–adrenergic receptor family: cloning and characterization of a human α2–adrenergic receptor subtype, the gene for which is located on chromosome 2. Proc Natl Acad Sci USA 1990; 87: 5094– 5098. 23 Birnbaumer L, Abramowitz J, Brown A M. Receptor–effectors coupling by G proteins. Biochim Biophys Acta 1990; 1031: 163– 224. 24 Dohlman H G, Thorner J, Caron M G, Lefkowitz R J. Model systems for the study of seven–transmembrane–segment receptors. Annu Rev Biochem 1991; 60: 653– 688. 25 Matsui H, Lefkowitz R J, Caron M G, Regan J W. Localization of the fourth membrane spanning domain as a ligand binding site in the human platelet alpha2–adrenergic receptor. Biochemistry 1989; 28: 4125– 4130. 26 Hibert M F, Trumpp–Kallmeyer S, Bruinvels A, Hoflack J. Three–dimensional models of neurotransmitter G–binding protein–coupled receptors. Mol Pharmacol 1991; 40: 8– 15. 27 Ostrowski J, Kjelsberg M A, Caron M G, Lefkowitz R J. Mutagenesis of the β2–adrenergic receptor: how structure elucidates function. Annu Rev Pharmacol Toxicol 1992: (in press). 28 Kurose H, Regan J W, Caron M G, Lefkowitz R J. Functional interactions of recombinant α2–adrenergic receptor subtypes and G proteins in reconstituted phospholipid vesicles. Biochemistry 1991; 30: 3335– 3341. 29 Isom L L, Limbird L E. What happens next? A hypothesis linking the biochemical and electrophysiological sequelae of alpha–2 adrenergic receptor occupancy with the diverse receptor–mediated physiological effects. In: LE Limbird, ed. The alpha–2 adrenergic receptors. Clifton, New Jersey: Humana Press, 1988: 323– 363. 30 Limbird L E. Receptors linked to inhibition of adenylate cyclase: additional signaling mechanisms. FASEB J 1988; 2: 2686– 2695. 31 Aghajanian G K, VanderMaelen C P. α–2 Adrenoceptor–mediated hyperpolarization of locus coeruleus neurons: intracellular studies in vivo. Science 1982: 215: 1394– 1396. 32 Maze M. Anesthesia and ion channel function in the autonomic nervous system. Int Anesthesiol Clin 1989; 27: 248– 258. 33 North R A. Drug receptors and the inhibition of nerve cells. Br J Pharmacol 1989; 98: 13– 28. 34 Doze V A, Chen B–X, Tinklenberg J A, Segal I S, Maze M. Pertussis toxin and 4–aminopyridine differentially affect the hypnotic–anesthetic action of dexmedetomidine and pentobarbital. Anesthesiology 1990; 73: 304– 307. 35 Maze M. Transmembrane signalling and the holy grail of anesthesia. (editorial) Anesthesiology 1990: 72: 959– 961. 36 Horn J P, McAfee D A. Alpha–adrenergic inhibition of calcium–dependent potentials in rat sympathetic neurons. J Physiol 1980; 301: 191– 204. 37 Lipscombe D, Kongsamut S, Tsien R W. a–Adrenergic inhibition of sympathetic neurotransmitter release mediated by modulation of N–type calcium–channel gating. Nature 1989; 340: 639– 642. 38 Hescheler J, Rosenthal W, Trautwein W, Schultz G. The GTP–binding protein, G, regulates neuronal calcium channels. Nature 1987; 325: 445– 447. 39 Fraser C M, Arakawa S, McCombie W R, Venter J C. Cloning, sequence analysis, and permanent expression of a human α2–adrenergic receptor in Chinese hamster ovary cells. Evidence for independent pathways of receptor coupling to adenylate cyclase attenuation and activation. J Biol Chem 1989; 264: 11754– 11761. 40 Michel M C, Brass L F, Williams A, Bokoch G M, LaMorte V J, Motulsky H J. α2–Adrenergic receptor stimulation mobilizes intracellular Ca2+ in human erythroleukemia cells. J Biol Chem 1989; 264: 4986– 4991. 41 Cotecchia S, Kobilka B K, Daniel K W et al. Multiple second messenger pathways of α–adrenergic receptor subtypes expressed in eukaryotic cells. J Biol Chem 1990; 265: 63– 69. 42 Jones S B, Halenda S P, Bylund D B. α2–Adrenergic receptor stimulation of phospholipase A2 and of adenylate cyclase in transfected Chinese hamster ovary cells is mediated by different mechanisms. Mol Pharmacol 1991; 39: 239– 245. 43 Unnerstall J R, Kopajtic T A, Kuhar M J. Distribution of α2 agonist binding sites in the rat and human central nervous system: analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents. Brain Res Rev 1984; 77: 69– 101. 44 Probst A, Cortes R, Palacios J M. Distribution of α–adrenergic receptors in the human brain stem: an autoradiographic study using [3H]p–aminoclonidine. Eur J Pharmacol 1985; 106: 477– 488. 45 De Jong W, Nijkamp F P. Centrally induced hypotension and bradycardia after administration of a–methylnoradrenaline into the area of the nucleus tractus solitarii of the rat. Br J Pharmacol 1976; 58: 593– 598. 46 van Zwieten P A. Drugs interacting with alpha adrenoceptors. Cardiovasc Drugs Ther 1989; 3: 121– 133. 47 Punnen S, Urbanski R, Krieger A J, Sapru H N. Ventrolateral medullary pressor area: site of hypotensive action of clonidine. Brain Res 1987; 422: 336– 346. 48 Bricca G, Dontenwill M, Molines A, Feldman J, Belcourt A, Bousquet P. Evidence for the existence of a homogenous population of imidazole receptors in the human brainstem. Eur J Pharmacol 1988; 150: 401– 402. 49 Bricca G, Dontenwill M, Molines A, Feldman J, Belcourt A, Bousquet P. The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem. Eur J Pharmacol 1989; 162: 1– 9. 50 Lehmann J, Koenig–Berard E, Vitou P. The imidazoline–preferring receptor. Life Sci 1989; 45: 1609– 1615. 51 C D Barnes, O Pompeiano (eds). Neurobiology of the locus coeruleus. Progress in brain research. Amsterdam: Elsevier, 1991: vol 88. 52 Cedarbaum J M, Aghajanian G K. Catecholamine receptors on locus coeruleus neurons: pharmacological characterization. Eur J Pharmacol 1977; 44: 375– 385. 53 DeSarro G B, Ascioti C, Froio F, Libri V, Nisticó G. Evidence that locus coeruleus is the site where clonidine and drugs acting at α1, – and α2–adrenoceptors affect sleep and arousal mechanisms. Br J Pharmacol 1987; 90: 675– 685. 54 Correa–Seles C, Rabin B C, Maze M. A hypnotic response to dexmedetomidine, an αagonist, is mediated in the locus coeruleus in rats. Anesthesiology 1992; 76: 948– 952. 55 Scheinin M, Schwinn D A. The locus coeruleus. Site of hypnotic actions of α2–adrenoceptor agonists? (editorial). Anesthesiology 1992; 76: 873– 875. 56 UnnerstallJ R, Kuhar M J. Mapping the α–adrenergic receptor in the central nervous system: a guide to structure and function. In: J M Stolk, D C U'Prichard, K Fuxe, eds. Epinephrine in the central nervous system. New York: Oxford University Press, 1984: 45– 59. 57 Sullivan A F, Dashwood M R, Dickenson A H. α2–Adrenoceptor modulation of nociception in rat spinal cord: location, effects and interactions with morphine. Eur J Pharmacol 1987; 138: 169– 177. 58 Ossipov M H, Suarez L J, Spaulding T C. Antinociceptive interactions between alpha2–adrenergic and opiate agonists at the spinal level in rodents. Anesth Analg 1989; 68: 194– 200. 59 McGrath J C. Evidence for more than one type of postjunctional a–adrenoceptor. Biochem Pharmacol 1982; 31: 467– 484. 60 Langer S Z, Hicks P E. Alpha–adrenoceptor subtypes in blood vessels: physiology and pharmacology. J Cardiovasc Pharmacol 1984: 6 (suppl.): S547– S558. 61 Nielsen H, Mortensen F V, Mulvany M J. Responses to noradrenaline in human subcutaneous resistance arteries are mediated by both α, – and α2–adrenoceptors. Br J Pharmacol 1990; 99: 31– 34. 62 Nielsen H, Thorn S M, Hughes A D, Martin G M, Mulvany M J, Sever P S. Postjunctional α2–adrenoceptors mediate vasoconstriction in human subcutaneous resistance vessels. Br J Pharmacol 1989; 97: 829– 834. 63 Kopia G A, Kopaciewicz L J, Ruffolo R R. Alpha adrenoceptor regulation of coronary artery blood flow in normal and stenotic canine coronary arteries. J Pharmacol Exp Ther 1986; 239: 641– 647. 64 Ishikawa Y, Umemura S, Uchino K. et al. Identification of an alpha2–adrenoceptor in human coronary arteries by radioligand binding assay. Life Sci 1991; 48: 2513– 2518. 65 Ruffolo R R, Nichols A J, Hieble J P. Functions mediated by alpha–2 adrenergic receptors. In: LE Limbird ed. The alpha–2 adrenergic receptors. Clifton, New Jersey: Humana Press, 1988: 187– 280. 66 Reid J L. The clinical pharmacology of clonidine and related central antihypertensive agents. Br J Clin Pharmacol 1981; 12: 295– 302. 67 Ruffolo R R, DeMarinis R M, Wise M, Hieble J P. Structure–activity relationships for alpha–2 adrenergic receptor agonists and antagonists. In: LE Limbird ed. The alpha–2 adrenergic receptors. Clifton, New Jersey: Humana Press, 1988: 115– 186. 68 Hoffmann B B, Lefkowitz R J. Catecholamines and sympathomimetic drugs. In: A G Gilman, T W Rail, A S Nies, P Taylor eds. Goodman and Gilman's The pharmacological basis of therapeutics, 8th ed. New York: Pergamon, 1990: 187– 220. 69 Isaac L. Clonidine in the central nervous system: site and mechanism of hypotensive action. J Cardiovasc Pharmacol 1980: 2 (Suppl. 1): S5– S19. 70 Gold M S, Pottash A C, Sweeney D R, Klever H D. Opiate withdrawal using clonidine. A safe, effective, and rapid nonopi–ate treatment. JAMA 1980; 243: 343– 346. 71 Franz D N, Hare B D, McCloskey K L. Spinal sympathetic neurons: possible sites of opiate–withdrawal suppression by clonidine. Science 1982; 215: 1643– 1645. 72 Wilkins A J, Jenkins W J, Steiner J A. Efficacy of clonidine in treatment of alcohol withdrawal state. Psychopharmacology 1983; 81: 78– 80. 73 Davison R, Kaplan K, Fintel D, Parker M, Anderson L, Haring O. The effect of clonidine on the cessation of cigarette smoking. Clin Pharmacol Ther 1988; 44: 265– 267. 74 Glassman A H, Stetner F, Walsh B T et al. Heavy smokers, smoking cessation, and clonidine. Results of a double–blind, randomized trial. JAMA 1988; 259: 2863– 2866. 75 Hughes J R. Clonidine, depression, and smoking cessation. JAMA 1988; 259: 2901– 2902. 76 Bond W S. Psychiatric indications for clonidine: the neurophar–macologic and clinical basis. J Clin Psychopharmacol 1986; 6: 81– 87. 77 Pintor C, Cella S G, Loche S et al. Clonidine treatment for short stature. Lancet 1987: i: 1226– 1230. 78 Dollery C T. Advantages and disadvantages of alpha2–adrenoceptor agonists for systemic hypertension. Am J Cardiol 1988; 61: 1D– 5D. 79 Mahieux F. Rilmenidine and vigilance. Am J Med 1989; 87: (suppl. 3C): 67S– 72S. 80 Safar M E. Rilmenidine: a novel antihypertensive agent. Am J Med 1989: 87 (suppl. 3C): 24– 29. 81 Gerber J G, Nies A S. Antihypertensive agents and the drug therapy of hypertension. In: A G Gilman, T W Rail, A S Nies, P Taylor eds. Goodman and Gilman's The pharmacological basis of therapeutics, 8th ed. New York: Pergamon, 1990: 784– 813. 82 Savola J–M, Ruskoaho H, Puurunen J, Salonen J S, Karki N T. Evidence for medetomidine as a selective and potent agonist at α2–adrenoceptors. J Auton Pharmacol 1986; 5: 275– 284. 83 Scheinin H, Virtanen R, MacDonald E, Lammintausta R, Scheinin M. Medetomidine – a novel α2–adrenoceptor agonist: a review of its pharmacodynamic effects. Prog Neuropsychopharm–acol Biol Psychiatry 1989; 13: 635– 651. 84 MacDonald E, Scheinin H, Scheinin M. Behavioral and neurochemical effects of medetomidine, a novel veterinary sedative. Eur J Pharmacol 1988; 158: 119– 127. 85 MacDonald E, Scheinin M, Scheinin H, Virtanen R. Comparison of the behavioral and neurochemical effects of the two optical enantiomers of medetomidine, a selective alpha–2–ad–renoceptor agonist. J Pharmacol Exp Ther 1991; 259: 848– 854. 86 Virtanen R, Savola J–M, Saano V, Nyman L. Characterization of the selectivity, specificity and potency of medetomidine as an α2–adrenoceptor agonist. Eur J Pharmacol 1988; 150: 9– 14. 87 Roizen M F, Kopin I J, Thoa N B, Zivin J, Muth E A, Jacobowitz D M. The effect of two anesthestic agents on norepinephrine and dopamine in discrete brain nuclei, fiber tracts, and terminal regions of the rat. Brain Res 1976; 110: 515– 522. 88 Aghajanian G K. Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Mature 1978; 276: 186– 188. 89 Miller R D, Way W L, Eger E I. The effects of alpha–methyldo–pa, reserpine, guanethidine, and iproniazid on minimum alveolar anesthetic requirement (MAC). Anesthesiology 1968; 29: 1153– 1158. 90 Roizen M F, White P F, Eger E I, Brownstein M. Effects of ablation of serotonin or norepinephrine brain–stem areas on halothane and cyclopropane MACs in rats. Anesthesiology 1978; 49: 252– 255. 91 Mueller R A, Smith R D, Spruill W A, Breese G R. Central monaminergic neuronal effects on minimum alveolar concentrations (MAC) of halothane and cyclopropane in rats. Anesthesiology 1975; 42: 143– 152. 92 Kaukinen S, Pyykkö K. The potentiation of halothane anaesthesia by clonidine. Acta Anaesthesiol Scand 1979; 23: 107– 111. 93 Bloor B C, Flacke W E. Reduction in halothane anesthetic requirement by clonidine, an alpha–adrenergic agonist. Anesth Analg 1982; 61: 741– 745. 94 Maze M, Birch B, Vickery R G. Clonidine reduces halothane MAC in rats. Anesthesiology 1987; 67: 868– 869. 95 Maze M, Vickery R G, Merlone S G, Gaba D M. Anesthetic and hemodynamic effects of the alpha2–adrenergic agonist, azepexole, in isoflurane–anesthetized dogs. Anesthesiology 1988; 68: 689– 694. 96 Segal I S, Vickery R G, Walton J K, Doze V A, Maze M. Dexmedetomidine diminishes halothane anesthetic requirements in rats through a postsynaptic alpha, adrenergic receptor. Anesthesiology 1988; 69: 818– 823. 97 Doze V A, Chen B–X, Li Z, Vickery R G, Maze M. Character ization of the alpha2 adrenoceptor–effector mechanism for the hypnotic action of MPV–1440 in rats. Anesthesiology 1988: 69 (suppl.): A619. 98 Doze V A, Chen B–X, Maze M. Dexmedetomidine produces a hypnotic–anesthetic action in rats via activation of central alpha–2 adrenoceptors. Anesthesiology 1989; 71: 75– 79. 99 Franks N P, Lieb W R. Volatile general anaesthetics activate a novel neuronal K+ current. Mature 1988; 333: 662– 664. 100 Weinger M B, Segal I S, Maze M. Dexmedetomidine, acting through central alpha–2 adrenoceptors, prevents opiate–induced muscle rigidity in the rat. Anesthesiology 1989; 71: 242– 249. 101 Hayashi Y, Sumikawa K, Maze M et al. Dexmedetomidine prevents epinephrine–induced arrhythmias through stimulation of central α2–adrenoceptors in halothane–anesthetized dogs. Anesthesiology 1991; 75: 113– 117. 102 Hoffman W E, Kochs E, Werner C, Thomas C, Albrecht R F. Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Anesthesiology 1991; 75: 328– 332. 103 Paalzow L. Analgesia produced by clonidine in mice and rats. J Pharm Pharmacol 1974; 26: 361– 363. 104 Spaulding T C, Fielding S, Venafro J J, Lai H. Antinociceptive activity of clonidine and its potentiation of morphine analgesia. Eur J Pharmacol 1979; 58: 19– 25. 105 Pertovaara A, Kauppila T, Tukeva T The effects of medetomidine, an a2–adrenoceptor agonist, in various pain tests. Eur J Pharmacol 1990; 179: 323– 328. 106 Ylisela E, Vainio O. Effects of medetomidine on the experimental auricular pain in dogs. Acta Vet Scand 1989; 85: 187– 189. 107 Fisher B, Zornow M H, Yaksh T L, Peterson B M. Antinociceptive properties of intrathecal dexmedetomidine in rats. Eur J Pharmacol 1991; 192: 221– 225. 108 Takano Y, Yaksh T L. Relative efficacy of spinal alpha–2 agonists, dexmedetomidine, clonidine and ST–91, determined in vivo by using N–ethoxycarbonyl–2–ethoxy–l,2–dihydroquinoli–ne, an irreversible antagonist. J Pharmacol Exp Ther 1991; 258: 438– 446. 109 Ossipov M H, Harris S, Lloyd P, Messineo E. An isobolographic analysis of the antinociceptive effect of systemically and intra–thecally administered combinations of clonidine and opiates. J Pharmacol Exp Ther 1990; 255: 1107– 1116. 110 Ossipov M H, Harris S, Lloyd P, Messineo E, Lin B–S, Bagley J. Antinociceptive interaction between opiodis and medetomidine: systemic additivity and spinal synergy. Anesthesiology 1990; 73: 1227– 1235. 111 Berthelsen S, Pettinger W A. A functional basis for classification of α–adrenergic receptors. Life Sci 1977; 21: 595– 606. 112 Clarke K W, Hall L W. A survey of anaesthesia in small animal practice: AVA/BSAVA report. J Assoc Vet Anaesth 1990; 17: 4– 10. 113 Kamerling S G, Cravens W M T, Bagwell C A. Objective assesment of detomidine–induced analgesia and sedation in the horse. Eur J Pharmacol 1988; 151: 1– 8. 114 Ghignone M, Calvillo O, Quintin L. Anesthesia and hypertension: the effect of clonidine on perioperative hemodynamics and isoflurane requirements. Anesthesiology 1987; 67: 3– 10. 115 Ghignone M, Noe C, Calvillo O, Quintin L. Anesthesia for ophthalmic surgery in the elderly: the effects of clonidine on intraocular pressure, perioperative hemodynamics, and anesthetic requirement. Anesthesiology 1988; 68: 707– 716. 116 Segal I S, Jarvis D J, Duncan S R, White P F, Maze M. Clinical efficacy of oral–transdermal clonidine combinations during the perioperative period. Anesthesiology 1991; 74: 220– 225. 117 Orko R, Pouttu J, Ghignone M, Rosenberg P H. Effect of clonidine on haemodynamic responses to endotracheal intubation and on gastric acidity. Acta Anaesthesiol Scand 1987; 31: 325– 329. 118 Wright P M C, Carabine U A, McClune S, Orr D A, Moore J. Preanaesthetic medication with clonidine. Br J Anaesth 1990; 65: 628– 632. 119 Richards M J, Skues M A, Jarvis A P, Prys–Roberts C. Total i.v. anaesthesia with propofol and alfentanil: dose requirements for propofol and the effect of premedication with clonidine. Br J Anaesth 1990; 65: 157– 163. 120 Flacke J W, Bloor B C, Flacke W E et al. Reduced narcotic requirement by clonidine with improved hemodynamic and adrenergic stability in patients undergoing coronary bypass surgery. Anesthesiology 1987; 67: 11– 19. 121 Ghignone M, Quintin L, Duke P C, Kehler C H, Calvillo O. Effects of clonidine on narcotic requirements and hemodynamic response during induction of fentanyl anesthesia and endotracheal intubation. Anesthesiology 1986; 64: 36– 42. 122 Roizen M F. Should we all have a sympathectomy at birth? Or at least preoperatively? (editorial) Anesthesiology 1988: 68: 482– 484. 123 Slogoff S. Perioperative ischemia. Semin Anesth 1990; 9: 1– 7. 124 Kauppila T, Kemppainen P, Tanila H, Pertovaara A. Effect of medetomidine, an alpha2–adrenoceptor agonist, on experimental pain in humans. Anesthesiology 1991; 74: 3– 8. 125 Jaakola M–L, Salonen M, Lehtinen R, Scheinin H. The analgesic action of dexmedetomidine – a novel α2–adrenoceptor agonist – in healthy volunteers. Pain 1991; 46: 281– 285. 126 Prys–Roberts C. Anaesthesia: a practical or impractical construct? (editorial) Br J Anaesth 1987: 59: 1341– 1345. 127 Gordh T E, Tamsen A. A study on the analgesic effect of clonidine in man. Acta Anaesthesiol Scand 1983: 27 (suppl.): 72. 128 Bernard J M, Lechevalier T, Pinaud M, Passuti N. Postoperative analgesia by intravenous clonidine. Anesthesiology 1991; 75: 577– 582. 129 Coombs D W, Saunders R L, Lachance D, Savage S, Ragnarsson T S, Jensen L E. Intrathecal morphine tolerance: use of intrathecal clonidine, DADLE, and intraventricular morphine. Anesthesiology 1985; 62: 358– 363. 130 Racle J P, Benkhara A, Poy J Y. Prolongation of isobaric bupivacaine spinal anesthesia with epinephrine and clonidine for hip surgery in elderly. Anesth Analg 1987; 66: 442– 446. 131 Bonnet F, Brun–Boisson V, Saada M, Boico O, Rostaing S, Touboul C. Dose–related prolongation of hyperbaric tetracaine spinal anesthesia by clonidine in humans. Anesth Analg 1989; 68: 619– 622. 132 Ota K, Namiki A, Ujike Y, Takahashi I. Prolongation of tetracaine spinal anesthesia by oral clonidine. Anesth Analg 1992; 75: 262– 264. 133 Tamsen A, Gordh T. Epidural clonidine produces analgesia. Lancet 1984: ii: 231– 232. 134 Glynn C, Dawson D, Sanders R. A double–blind comparison between epidural morphine and epidural clonidine in patients with chronic non–cancer pain. Pain 1988; 34: 123– 128. 135 Bonnet F, Boico O, Rostaing S et al. Postoperative analgesia with extradural clonidine. Br J Anaesth 1989; 63: 465– 469. 136 Bonnet F, Boico O, Rostaing S, Loriferne J–F, Saada M. Cloni–dine–induced analgesia in postoperative patients: epidural versus intramuscular administration. Anesthesiology 1990; 72: 423– 427. 137 Eisenach J C, Rauck R L, Buzzanell C, Lysak S Z. Epidural clonidine analgesia for intractable cancer pain: phase I. Anesthesiology 1989; 71: 647– 652. 138 Mendez R, Eisenach J C, Kashtan K. Epidural clonidine analgesia after cesarean section. Anesthesiology 1990; 73: 848– 852. 139 Huntoon M, Eisenach J C, Boese P. Epidural clonidine after cesarean section. Anesthesiology 1992; 76: 187– 193. 140 Lund C, Qyitzau S, Greulich A, Hjortso N–C, Kehlet H. Comparison of the effects of extradural clonidine with those of morphine on postoperative pain, stress responses, cardiopulmonary function and motor and sensory block. Br J Anaesth 1989; 63: 516– 519. 141 Gordh T. Epidural clonidine for treatment of postoperative pain after thoracotomy. A double–blind placebo–controlled study. Acta Anaesthesiol Scand 1988; 32: 702– 709. 142 van Essen E J, Bovill J G, Ploeger E J. Extradural clonidine does not potentiate analgesia produced by extradural morphine after meniscectomy. Br J Anaesth 1991; 66: 237– 241. 143 Zeigler D, Lynch S A, Muir J, Benjamin J, Max M B. Transdermal clonidine versus placebo in painful diabetic neuropathy. Pain 1992; 48: 403– 408. 144 Aghajanian G K, Wang Y–Y. Common α2– and opiate effector mechanisms in the locus coeruleus: intracellular studies in brain slices. Neuropharmacology 1987; 26: 793– 799. 145 Yaksh T L, Hammond D L, Tyce G M. Functional aspects of bulbospinal monoaminergic projections in modulating processing of somatosensory information. Fed Proc 1981; 40: 2786– 2794. 146 Solomon R E, Gebhardt G F. Intrathecal morphine and clonidine. Antinociceptive tolerance and cross–tolerance and effects on blood pressure. J Pharmacol Exp Ther 1988; 245: 444– 454. 147 Yaksh T L. Pharmaology of spinal adrenergic systems which modulate spinal noceceptive processing. Pharmacol Biochem Behav 1985; 22: 845– 858. 148 Kuraishi Y, Hirota N, Sato Y, Kaneko S, Satoh M, Takagi H. Noradrenergic inhibition of the release of substance P from the primary afferents in the rabbit spinal dorsal horn. Brain Res 1985; 359: 177– 182. 149 Archer T, Jonsson G, Minor B G, Post C. Noradrenergic–serotonergic interactions and nociception in the rat. Eur J Pharmacol 1986; 120: 295– 307. 150 Nakagawa I, Omote K, Kitahata L M, Collins J G, Murata K. Serotonergic mediation of spinal analgesia and its interaction with noradrenergic systems. Anesthesiology 1990; 73: 474– 478. 151 Gordh T, Jansson I, Hartvig P, Gillberg P G, Post C. Interactions between noradrenergic and cholinergic mechanisms involved in spinal nociceptive processing. Acta Anaesthesiol Scand 1989; 33: 39– 47. 152 Engelman E, Lipszyc M, Gilbart E et al. Effects of clonidine on anesthetic drug requirements and hemodynamic response during aortic surgery. Anesthesiology 1989; 71: 178– 187. 153 Quintin L, Bonnet F, Macquin I, Szekely B, Becquemin J P, Ghignone M. Aortic surgery: effect of clonidine on intraoperative catecholaminergic and circulatory stability. Acta Anaesthesiol Scand 1990; 34: 132– 137. 154 Woodcock T E, Millard R K, Dixon J, Prys–Roberts C. Clonidine premedication for isoflurane–induced hypotension. Br J Anaesth 1988; 60: 388– 394. 155 Toivonen J, Kaukinen S. Clonidine premedication: a useful adjunct in producing deliberate hypotension. Acta Anaesthesiol Scand 1990; 34: 653– 657. 156 Pouttu J, Scheinin B, Rosenberg P H, Viinamäki O, Scheinin M. Oral premedication with clonidine: effects on stress responses during general anaesthesia. Acta Anaesthesiol Scand 1987; 31: 730– 734. 157 Aho M, Lehtinen A–M, Laatikainen T, Korttila K. Effects of intramuscular clonidine on hemodynamic and plasma βendorphin responses to gynecologic laparoscopy. Anesthesiology 1990; 72: 797– 802. 158 Pouttu J, Tuominen M, Scheinin M, Rosenberg P H. Effects of oral clonidine premedication on concentrations of Cortisol and monoamine neurotransmitters and their metabolites in cerebrospinal fluid and plasma. Acta Anaesthesiol Scand 1989; 33: 137– 141. 159 Timmermans PBMWM, van Zwieten P A. α2–Adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem 1982; 25: 1389– 1401. 160 Flacke J W, Flacke W E, Bloor B C, Mclntee D F. Hemodynamic effects of dexmedetomidine, an α2–adrenergic agonist, in autonomically denervated dogs. J Cardiovasc Pharmacol 1990; 16: 616– 623. 161 Peden C J, Prys–Roberts C. Dexmedetomidine – a powerful new adjunct to anaesthesia? (editorial) Br J Anaesth 1992: 68: 123– 125. 162 Scheinin M, Kallio A, Koulu M, Arstila M, Viikari J, Scheinin H. Dose–finding and tolerability study of medetomidine in four healthy volunteers. Curr Ther Res 1987; 41: 637– 646. 163 Scheinin M, Kallio A, Koulu M, Viikari J, Scheinin H. Sedative and cardiovascular effects of medetomidine, a novel selective α2adrenoceptor agonist, in healthy volunteers. Br J Clin Pharmacol 1987; 24: 443– 451. 164 Kallio A, Koulu M, Scheinin H, Viikari J, Scheinin M. Acute effects of medetomidine, a selective α2–adrenoceptor agonist, on pituitary hormone and Cortisol secretion in man. Acta Endocrinol 1988; 119: 11– 15. 165 Kallio A, Scheinin M, Koulu M et al. Effects of dexmedetomidine, a selective α2–adrenoceptor agonist, on hemodynamic control mechanisms. Clin Pharmacol Ther 1989; 46: 33– 42. 166 Kallio A, Saraste M, Scheinin M, Hartiala J, Scheinin H. Acute hemodynamic effects of medetomidine and clonidine in healthy volunteers: a noninvasive echocardiographic study. J Cardiovasc Pharmacol 1990; 16: 28– 33. 167 Aantaa R E, Kanto J H, Scheinin M, Kallio A M I, Scheinin H. Dexmedetomidine premedication for minor gynecologic surgery. Anesth Analg 1990; 70: 407– 413. 168 Aantaa R, Kanto J, Scheinin M, Kallio A, Scheinin H. Dexmedetomidine, an α–adrenoceptor agonist, reduces anesthetic requirements for patients undergoing minor gynecologic surgery. Anesthesiology 1990; 73: 230– 235. 169 Kallio A, Salonen M, Forssell H, Scheinin H, Scheinin M, Tuominen J. Medetomidine premedication in dental surgery –a double–blind cross–over study with a new α2–adrenoceptor agonist. Acta Anaesthesiol Scand 1990; 34: 171– 175. 170 Housmans P R. Effects of dexmedetomidine on contractility, relaxation, and intracellular calcium transients of isolated ventricular myocardium. Anesthesiology 1990; 73: 919– 922. 171 Aantaa R, Kanto J, Scheinin M. Intramuscular dexmedetomidine, a novel alpha2–adrenoceptor agonist, as premedication for minor gynaecologic surgery. Acta Anaesthesiol Scand 1991; 35: 283– 288. 172 Aantaa R, Jaakola M–L, Kallio A, Kanto J, Scheinin M, Vuorinen J. A comparison of dexmedetomidine, an alpha2adrenoceptor agonist, and midazolam as intramuscular premedication for minor gynaecologic surgery. Br J Anaesth 1991; 67: 402– 409. 173 Aho M, Lehtinen A–M, Erkola O, Korttila K. A novel α2–agonist, dexmedetomidine as intramuscular premedication for laparoscopy. Anesth Analg 1991: 72 (suppl.): S2. 174 Aho M, Lehtinen A–M, Erkola O, Kallio A, Korttila K. The effect of intravenously administered dexmedetomidine on perioperative hemodynamics and isoflurane requirements in patients undergoing abdominal hysterectomy. Anesthesiology 1991; 74: 997– 1002. 175 Aho M S, Erkola O A, Scheinin H, Lehtinen A–M, Korttila K. Effect of intravenously administered dexmedetomidine on pain after laparoscopic tubal ligation. Anesth Analg 1991; 73: 112– 118. 176 Scheinin B, Lindgren L, Randell T, Scheinin H, Scheinin M. Dexmedetomidine attenuates sympathoadrenal responses to tracheal intubation and reduces the need for thiopentone and peroperative fentanyl. Br J Anaesth 1992; 68: 126– 131. 177 Jaakola M–L, Ali–Melkkilä T, Kanto J, Scheinin M, Kallio A, Scheinin H. Reduced intraocular pressure, adrenergic response, and anesthetic requirements by dexmedetomidine in patients scheduled for ophthalmic surgery. Br J Anaesth 1992; 68: 570– 575. 178 Jaakola M–L, Kanto J, Scheinin H, Kallio A. Intramuscular dexmedetomidine as premedication in elective abdominal hysterectomy. Acta Anaesthesiol Scand 1991; 35: S196. 179 Metz S A, Halter J B, Robertson R P. Induction of defective insulin secretion and impaired glucose tolerance by clonidine. Selective stimulation of metabolic alpha–adrenergic pathways. Diabetes 1978; 27: 554– 562. 180 Bailey P L, Sperry R J, Johnson G K et al. Respiratory effects of clonidine alone and combined with morphine, in humans. Anesthesiology 1991; 74: 43– 48. 181 Jarvis D A, Duncan S R, Segal I S, Maze M. Ventilatory effects of clonidine alone and in the presence of alfentanil, in human volunteers. Anesthesiology 1992; 76: 899– 905. 182 Furst S R, Weinger M B. Dexmedetomidine, a selective αagonist, does not potentiate the cardiorespiratory depression of alfentanil in the rat. Anesthesiology 1990; 72: 882– 888. 183 Schmeling W T, Kampine J P, Roerig D L, Waltier D C. The effects of the stereoisomers of the α2–adrenergic agonist medetomidine on systemic and coronary hemodynamics in conscious dogs. Anesthesiology 1991; 75: 499– 511. 184 Nguyen D, Abdul–Rasool I, Ward D et al. Ventilatory effects of dexmedetomidine, atipamezole, isoflurane in dogs. Anesthesiology 1992; 76: 573– 579. 185 Belleville J P, Ward D S, Bloor B C, Maze M. Ventilatory effects of dexmedetomidine in humans. Anesthesiology 1990: 73 (suppl.): A1167. 186 Quintin L, Viale J P, Annat G et al. Oxygen uptake after major abdominal surgery: effect of clonidine. Anesthesiology 1991; 74: 236– 241. 187 Bertel O, Conen D, Radii E W, Miiller J, Lang C, Dubach U C. Nifedipine in hypertensive emergencies. Br Med J 1983; 286: 19– 21. 188 Kanawati I S, Yaksh T L, Anderson R E, Marsh R W. Effects of clonidine on cerebral blood flow and the response to arterial CO2. J Cereb Blood Flow Metab 1986; 6: 358– 365. 189 Karlsson B R, Forsman M, Roald O K, Heier M S, Steen P A. Effect of dexmedetomidine, a selective and potent α2–agonist, on cerebral flow and oxygen consumption during halothane anesthesia in dogs. Anesth Analg 1990; 71: 125– 129. 190 Zornow M H, Fleischer J E, Scheller M S, Nakakimura K, Drummond J C. Dexmedetomidine, an a2–adrenergic agonist, decreases cerebral blood flow in the isoflurane–anesthetized dog. Anesth Analg 1990; 70: 624– 630. 191 Karhuvaara S, Kallio A, Salonen M, Tuominen J, Scheinin M. Rapid reversal of α–adrenoceptor agonist effects by atipamezole in human volunteers. Br J Clin Pharmacol 1991; 31: 160– 165. 192 Dubocovich M L. Presynaptic alpha–adrenoceptors in the central nervous system. Ann NY Acad Sci 1984; 430: 7– 25. Citing Literature Volume37, Issue5July 1993Pages 433-448 ReferencesRelatedInformation
Referência(s)